EBOS prepped for life after CWH

Pharmaceutical wholesaler reports strong growth ahead of Chemist Warehouse’s switch to rival  Symbion’s parent company, EBOS Group is reporting “strong normalised growth” for the first half of the 2023/24 financial year, excluding its Chemist Warehouse (CWH) business.  Releasing its half-year results, EBOS noted that its healthcare business had reported its underlying EBITDA (earnings before interest, taxes,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous NAPSA approves UNSW branch
Next Cannabis growth spiral sees stakeholders meet